No Detail Found!

Meloxicam loaded hydroxypropyl methylcellulose (HPMC) microparticulate: Fabrication, characterization and in vivo pharmacokinetic assessment

Author(s)
Syed Abdul Wasay Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan
Syed Umer Jan Faculty of Pharmacy and Health Sciences, University of Balochistan,Quetta,Pakistan
Muhammad Akhtar Department of Medical Laboratory Technology, Faculty of Medicine and Allied Health Sciences, The Islamia University of Bahawalpur,Bahawalpur,Pakistan;Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur,Bahawalpur,Pakistan
Rabbiya Ahmad Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur,Bahawalpur,Pakistan
Pervaiz Akhtar Shah Punjab University College of Pharmacy, University of the Punjab,Lahore,Pakistan
Ghulam Razaque Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan
Shafi Muhammad Faculty of Pharmacy and Health Sciences, University of Balochistan,Quetta,Pakistan
Nisar Ahmad Shahwani Faculty of Pharmacy and Health Sciences, University of Balochistan,Quetta,Pakistan
Mohammad Younis Faculty of Pharmacy and Health Sciences, University of Balochistan,Quetta,Pakistan
Ghulam Mustafa Shahwani Faculty of Pharmacy and Health Sciences, University of Balochistan,Quetta,Pakistan
Jahangir Khan Achakzai Department of Natural and Basic Sciences, University of Turbat (KECH),Turbat,Pakistan
Abstract
Meloxicam (MEL) is an oxicam derivative with low water solubility that is useful in the treatment of colorectal cancer (CRC) as a COX-2 inhibitor. MEL-loaded HPMC micro particles were fabricated using an oil-in-oil (o/o) emulsion solvent evaporation (ESE) method. FTIR, XRD, particle size analysis, DSC, SEM and in vitro dissolution investigation were utilized to evaluate the produced micro particles physiochemically. Finally, rabbits were used as animal models in an in vivo pharmacokinetic study to assess the MEL concentration in the plasma of rabbits. Pure MEL, F1 and F2 were given to rabbits by a single dose for in vivo pharmacokinetic investigations. The XRD and DSC results confirmed the transformation of MEL from its crystalline nature to the amorphous state in micro particles. The formulations F1 and F2 particle sizes were determined 92.43µm and 163.26µm, respectively. The prepared micro particles had a smooth, non-porous, and spherical surface. In comparison to the pure drug (22.4%), the F1 and F2 cumulative drug release (%) was 86.19% and 79.57%, respectively. Pure MEL, F1 and F2 have estimated Cmax values of 7.21, 25.41 and 22.38µg/mL, respectively. MEL had a half-life of 19.98 hours, which rose to 22.19 hours and 24.75 hours for F1 and F2, respectively. MEL, F1 and F2 had AUC0-a values of 116.034, 445.95 and 462.72µg/mL*h, respectively. Considering these aspects, MEL-loaded HPMC micro particles may have the potential to better the delivery and control the release of drug that is not easily dissolved in water which could lead to improved therapeutic efficacy and limited side effects.
Publication Details
Page(s) 1251-1260
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: S4, Year: 2022

Request the full text from PASTIC

Keywords
Micro particles, Meloxicam, HPLC, pharmacokinetics study, HPMC, Validation
References
Abadi SSH,Gangadharappa H,Balamuralidhara VJ H .2020 .Development of colon-specific mucoadhesive meloxicam microspheres for the treatment of CFAinduced arthritis in rats. Int. J. Polyme. Mate. Polyme. Biomater, 70(12) : 849-869.
Avdeef ,Development Drug .2012 .Permeability PAMPA. , : 319-498.
Bae JW,Kim MJ,Jang CG,Lee SYJJOCB .2007 .Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. J. Chromatograp. B, 859(1) : 69-73.
Chaudhari VS,Borkar RM,Murty US,Banerjee S US .2020 .Analytical method development and validation of reverse-phase high-performance liquid chromatography (RP-HPLC) method for simultaneous quantifications of quercetin and piperine in dual-drug loaded nanostructured lipid carriers. J. Pharmaceu. Biomed Analy, 186 : 113325.
Chen YC,Moseson DE,Richard CA,Swinney MR,Horava SD,Oucherif KA,Cox AL,Hawkins ED,Li Y .2022 .Development of hot-melt extruded drug/polymer matrices for sustained delivery of meloxicam. J. Controlled Release, 342 : 189-200.
Hombreiro-Perez M,Siepmann J,Zinutti C,Lamprecht A,Ubrich N,Hoffman M,Bodmeier R,Maincent P .2003 .Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling. J. Controlled Release, 88 : 413-428.
Jafari H,Mahdavinia GR,Kazemi B,Ehrlich H,Joseph Y,Rahimi-Nasrabadi M .2021 .Highly efficient sunitinib release from pH-responsive mHPMC@ Chitosan core-shell nanoparticles. J. Carbohydrate Polymers, 258 : 117719.
Jiang Q,Wang J,Ma P,Liu C,Sun M,Sun Y,He Z Y .2018 .Ion-pair formation combined with a penetration enhancer as a dual strategy to improve the transdermal delivery of meloxicam. J. Drug Deliv. Trans. Res., 8(1) : 64-72.
Kashif PM,Madni A,Ashfaq M,Rehman M,Mahmood MA,Khan MI,Tahir N MI .2017 .Development of Eudragit RS 100 microparticles loaded with ropinirole: optimization and in vitro evaluation studies. J. AAPS Pharmscitech, 18(5) : 1810-1822.
Katona G,Balogh GT,Dargo G,Gáspár R,Márki Á,Ducza E,Sztojkov-Ivanov A,Tomosi F,Kecskeméti G,Janáky T .2020 .Development of meloxicamhuman serum albumin nanoparticles for nose-to-brain delivery via application of a quality by design approach. J. Pharmaceutics, 12(2) : 97.
Khan KU,Minhas MU,Sohail M,Badshah SF,Abdullah O,Khan S,Munir A,Suhail M .2021 .Synthesis of PEG-4000-co-poly (AMPS) nanogels by cross-linking polymerization as highly responsive networks for enhancement in meloxicam solubility. J. Drug Devel. Indust. Pharma, 47(3) : 465-476.
Krier F,Brion M,Debrus B,Lebrun P,Driesen A,Ziemons E,Evrard B,Hubert P .2011 .Optimisation and validation of a fast HPLC method for the quantification of sulindac and its related impurities. J. Pharmaceut. Biomed Analy, 54(4) : 694-700.
Maqbool I,Akhtar M,Ahmad R,Sadaquat H,Noreen S,Batool A,Khan SU .2020 .Novel multiparticulate pH triggered delayed release chronotherapeutic drug delivery of celecoxib-β-cyclodextrin inclusion complexes by using Box-Behnken design. Eue. J. Pharm. Sci., 146 : 105254.
Montejo C,Barcia E,Negro S,Fernández-Carballido A .2010 .Effective antiproliferative effect of meloxicam on prostate cancer cells: Development of a new controlled release system. Int. J. Pharmaceutics, 387(1-2) : 223-229.
Patel MM .2017 .Formulation and development of didependent microparticulate system for colon-specific drug delivery. J. Drug Deliv. Trans. Res, 7(2) : 312-324.
Q8 I .2005 .ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Topic Q9: Quality Risk Management Geneva. , : .
Rashid M,Kaur V,Hallan SS,Sharma S,Mishra N S .2016 .Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi, 24(4) : 458-472.
Fitzgerald Ricciotti E,GA Ricciotti E .2011 .Prostaglandins and inflammation. J. Arteriosclerosis, Thrombo. Vascular Biol, 31(5) : 986-1000.
Sharma M,Kohli S,Dinda A .2015 .In-vitro and invivo evaluation of repaglinide loaded floating microspheres prepared from different viscosity grades of HPMC polymer. Saudi Pharm. J., 23(6) : 675-682.
Sheikh FA,Aamir MN,Haseeb MT,Bukhari SNA,Ul Haq MF,Akhtar N MF .2021 .Design, physicochemical assessment and pharmacokinetics of a nontoxic orodispersible film for potential application in musculo-skeletal disorder. J. Drug Deliv. Sci. Tech, 65 : 102726.
Shi Y,Liu Z,Yang Y,Xu X,Li Y,Li T Y .2017 .Design of poly (mPEGMA-co-MAA) hydrogel-based mPEGb-PCL nanoparticles for oral meloxicam delivery. J. Matr. Sci. Eng, 76(1) : 975-984.
Suzuki R,Yamamoto M,Saka H,Taniguchi H,Shindoh J,Tanikawa Y,Nomura F,Gonda H,Imaizumi K,Hasegawa Y .2009 .A phase II study of carboplatin and paclitacel with meloxicam. J. Lung Cancer, 63(1) : 72-76.
Wasay SA,Jan SU,Akhtar M,Noreen S,Gul R .2022 .Developed meloxicam loaded microparticles for colon targeted delivery: Statistical optimization, physicochemical characterization and in-vivo toxicity study. PLoS ONE, 17(4) : e0267306.
0

Citations

0

Downloads

8

Views